Discontinuing or withholding primary prophylaxis against Mycobacterium avium in patients on successful antiretroviral combination therapy. The Swiss HIV Cohort Study
| Autor: | Marco Rossi, Hansjakob Furrer, Amalio Telenti, Bruno Ledergerber |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Adult
Male medicine.medical_specialty Combination therapy Anti-HIV Agents Immunology HIV Infections Cohort Studies Pharmacotherapy Acquired immunodeficiency syndrome (AIDS) Internal medicine medicine Immunology and Allergy Humans Sida Aged Mycobacterium avium-intracellulare Infection biology AIDS-Related Opportunistic Infections business.industry Incidence (epidemiology) Middle Aged medicine.disease biology.organism_classification Confidence interval Surgery CD4 Lymphocyte Count Infectious Diseases Chemoprophylaxis Female business Switzerland Cohort study |
| Zdroj: | AIDS (London, England). 14(10) |
| ISSN: | 0269-9370 |
| Popis: | Objective: To assess the safety of discontinuing or withholding primary prophylaxis against disseminated Mycobacterium avium infection (MAC) in HIV infected patients on successful antiretroviral combination therapy. Setting: National prospective multicentre cohort study. Design: HIV-infected patients were eligible for the analysis if: (i) they had a history of at least two CD4 cell counts < 50 x 10 6 /l; (ii) they had never had MAC; (iii) they had discontinued or never begun primary prophylaxis against MAC; (iv) they received antiretroviral therapy and demonstrated an increase in CD4 cell counts to ≥ 100 × 10 6 /l that was sustained for at least 12 weeks. From this time point until last follow-up, incidence of disseminated MAC disease was measured, and 99% confidence intervals were calculated assuming a Poisson distribution of events. Results: Two-hundred and fifty-three patients (22.5% female; median age, 37 years, 30% injecting drug users) were eligible for analysis. Sixty-six per cent were in Centers for Disease Control and Prevention (CDC) stage C, and 28% were in CDC stage B. Their median nadir CD4 cell count was 10 × 10 6 /l, the median duration of CD4 cell count < 50 x 10 6 /l was 12 months. During a total follow-up of 364.3 patient-years there was no case of disseminated MAC. The one-sided 99% confidence limit for incidence density of MAC was 1.3 per 100 person-years. Conclusion: Discontinuing or withholding primary prophylaxis against MAC is safe in patients who have a sustained increase in their CD4 cell count to ≥ 100 × 10 6 /l. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|